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Abstract
Background—In 2008, the first clinic for women involved in high risk sexual behaviour was
established in Kampala, offering targeted HIV prevention. This paper describes rates,
determinants and trends of HIV incidence over 3 years.
Methods—1027 women at high risk were enrolled into a closed cohort. At 3-monthly visits, data
were collected on socio-demographic variables and risk behaviour; biological samples were tested
for HIV and other STIs. Hazard ratios (HR) for HIV incidence were estimated using Cox
proportional hazards regression, among the 646 women HIV negative at enrolment.
Results—HIV incidence was 3.66/100pyr and declined from 6.80/100pyr in the first calendar
year to 2.24/100pyr and 2.53/100pyr in the following years (P-trend=0.003). Socio-demographic
and behavioural factors independently associated with HIV incidence were younger age, younger
age at first sex, alcohol use (including frequency of use and binge drinking), number of paying
clients in the past month, inconsistent condom use with clients, and not being pregnant. HIV
incidence was also independently associated with M. genitalium infection at enrolment
(aHR=2.28, 95%CI: 1.15-4.52), and with N. gonorrhoeae (aHR=5.91, 95%CI: 3.04-11.49) and T.
vaginalis infections at the most recent visit (aHR=2.72, 95%CI: 1.27-5.84). The PAF of HIV
incidence for alcohol use was 63.5% (95%CI 6.5%-85.8%), and for treatable STI/RTI was 70.0%
(95%CI 18.8%-87.5%).
Conclusions—Alcohol use and STIs remain important risk factors for HIV acquisition, which
call for more intensive control measures in women at high risk. Further longitudinal studies are
needed to confirm the association between Mycoplasma genitalium and HIV acquisition.
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Introduction
Core groups involved in high risk sexual behaviour, such as female sex workers (FSW), play
an important role both in the initial establishment of sexually transmitted HIV epidemics and
in the later contracting phases, as HIV transmission again becomes more concentrated in
high risk groups [1]. Uganda is currently undergoing this later stage epidemic, and risk
reduction interventions for high risk groups are needed to prevent a resurgence of HIV in
both core groups and the general population.
Several sub-Saharan African countries have successfully implemented HIV prevention
interventions for FSW, combining improved access to treatment for sexually transmitted
infections (STIs), condom promotion, and voluntary HIV counselling and testing (VCT)
[2-5]. In low income countries, such focused interventions are effective in reducing HIV and
STI acquisition [6], and are cost-effective in preventing new HIV infections [7].
In 2008, following a request from the Ugandan National AIDS Programme, the MRC
Uganda Research Unit on AIDS recruited the first cohort of women involved in high-risk
sexual behaviour in Kampala with the aim to study the size, determinants and dynamics of
the HIV epidemic in this population. Women involved in sex work and/or employed in
entertainment facilities were recruited from red-light-areas in Southern Kampala. A stand-
alone clinic was established, offering a comprehensive package of HIV prevention
interventions. Baseline data estimated HIV prevalence as 37% (95% CI 34%–40%) as well
as high rates of other STIs, frequent unsafe sex with clients (40% inconsistent condom use
in last month) and alcohol use (78%)[8,9].
The current paper presents the rates and determinants of HIV seroconversion as well as the
changes over time in HIV incidence during follow-up in this high-risk cohort.
Methods
Study population and clinical procedures
Between April 2008 and April 2009, women likely to be involved in high risk sexual
behaviour were recruited from red-light-areas in Southern Kampala. The study population,
recruitment process and study procedures have been described in detail previously [8].
Briefly, self-reporting FSW and/or women employed in entertainment facilities were
approached at night by our field workers. They were invited to visit the Good Health for
Women Project (GHWP) clinic for screening and enrolment into the cohort. Among 1214
women screened, 79 were not eligible, 106 did not return for their enrolment visit and 2
declined consenting. Among the remaining 1027 women, 95% reported sex work. Enrolled
women were scheduled for 3-monthly follow-up visits. At every scheduled visit, women
were interviewed about their socio-demographic characteristics, sexual risk behaviour,
alcohol use, intravaginal practices, reproductive health history and symptoms of STIs. VCT,
family planning and antenatal care were offered. Blood was tested for HIV, HSV2 and
syphilis. A speculum examination was performed and two endocervical specimens were
collected, one for the diagnosis of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis
(CT) infection and one for diagnosis of Mycoplasma genitalium (MG). One high vaginal
specimen was collected and inoculated for culture of Trichomonas vaginalis (TV), another
to prepare a slide for the detection of bacterial vaginosis (BV) and of Candida infection.
Women with symptomatic STIs were treated syndromically on the spot. Women with
asymptomatic STIs were treated as soon as laboratory results became available. Health-
education on HIV/STI, risk reduction counselling, and condom demonstration and
promotion were provided.
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After the first follow-up year genital specimens were collected and tested only 6-monthly.
Due to financial constraints, testing for MG was limited to stored specimens from the
baseline visit. Throughout the study, free primary health care was offered for participating
women and their children aged less than 5 years old. All participants with confirmed HIV
infection had their CD4-count measured: women eligible for antiretroviral therapy (ART)
were referred to an HIV-care centre. Those not yet eligible were provided with
cotrimoxazole prophylaxis and their CD4-count was measured at subsequent visits.
Laboratory procedures
Serum specimens were tested for antibodies against HIV-1 (Abbott Determine HIV-1/2 with
confirmation by two independent ELISA tests: Vironostika Uniform II plus O, Murex HIV
1.2.O), HSV-2 (IgG ELISA test, Kalon Biologicals Ltd, UK) and for syphilis (RPR Biotec
and TPHA Biotec). NG and CT were diagnosed on endocervical specimens using the
Amplicor PCR test (Roche Diagnostic Systems Inc., Branchburg, NJ) and TV was detected
using the commercial culture kit (InPouch TV, BioMed Diagostics, White City, Oregon).
Microscopy on a gram-stained vaginal specimen was performed to diagnose BV (using
Nugent’s criteria) and Candida infection. Laboratory testing for all these infections was
performed at the central laboratories of the MRC/UVRI Uganda Unit in Entebbe.
For the diagnosis of MG, endocervical specimens, collected using Cobas Amplicor STM
collection tubes (Roche Diagnostic Systems Inc., Branchburg, NJ), were tested using a
commercially available Real-TM PCR assay (Sacace Biotechnologies, Como, Italy) at the
Centre for HIV and Sexually Transmitted Infections, National Institute for Communicable
Diseases, National Health Laboratory Service in Johannesburg. Further details of this PCR
test have been reported previously [9].
Statistical analysis
Data were double entered in Access and analysed using STATA 11.0 (Stata Inc., TX).
Women were censored at the earliest of the date of HIV seroconversion, date last seen, or
31st March 2011. Cox proportional hazards regression with time-varying covariate approach
was used to estimate hazard ratios (HR) for HIV seroconversion (assumed to take place
midway between the last negative and first positive serology result). For time-changing
exposures, the measurement at the most recent visit was used. MG results were only
available from the baseline visit, while for other STIs the results at the most recent visit were
used. Syphilis was categorized as no infection (RPR-TPHA-), past infection (RPR-TPHA+),
low titre active infection (RPR+TPHA+ with RPR titre <8) and high titre active infection
(RPR+TPHA+ with RPR titre ≥8).
Determinants of HIV seroconversion were first examined using age-adjusted analysis, as age
was a strong a-priori confounder. The multivariable analysis was conducted using a
hierarchical conceptual framework [10], grouping variables in three levels as
sociodemographic, behavioral/reproductive health and clinical/biological.
Sociodemographic factors associated in age-adjusted analysis (P≤0.10) were included in a
multivariable model and retained in a core model if they remained independently associated
with HIV seroconversion. Behavioral and reproductive factors were added to this model one
by one and included in a multivariable model if P≤0.10. Factors remaining significant after
adjustment for each other and the socio-demographic factors were retained. Factors
describing alcohol use were treated separately to avoid co-linearity. The same steps were
repeated with clinical and biological factors. Ordered variables were included as linear
trends if there was no evidence of non-linearity using a likelihood ratio test.
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Population attributable fractions (PAFs) of HIV acquisition for risk factors in the final
model were estimated using the formula p(aHR-1)/aHR, with p=proportion of cases exposed
and aHR= adjusted hazard ratio [11].
Ethical considerations
Informed consent was obtained from all study participants. The study was approved by the
Science and Ethics Committee of the Ugandan Virus Research Institute, the Uganda
National Committee for Science and Technology and the Ethics Committee of the London
School of Hygiene and Tropical Medicine.
Results
HIV incidence
Of 1027 women enrolled, 646 were HIV-negative. The total follow-up time contributing to
HIV seroconversion analyses was 1147 person-years (pyr), with median time in the cohort
of 2.1 years (range 0.1-3.0 years). There was high retention in the cohort, with 77% of
women attending the 12 month visit, and 74% attending the 18 month visit. Forty-two
women seroconverted (HIV incidence rate: 3.66/100 pyr; 95%CI: 2.71-4.96/100 pyr). HIV
seroconversion decreased substantially with time-in-study, from 8.26/100 pyr in the first 6
months to 2.01/100 pyr in the period 2.5-3 years after inclusion (age-adjusted p-value for
trend=0.002, Figure 1). HIV seroconversion also decreased substantially with calendar time
from 6.80/100 pyr in the period April 2008-March 2009, to 2.53/100 pyr in the period April
2010-March 2011 (age-adjusted p-value for trend=0.003).
Factors associated with HIV seroconversion
In age-adjusted analyses, the only socio-demographic factor associated with HIV
seroconversion was calendar time (Table 1), and age and calendar time were retained in the
hierarchical model. Behavioural and reproductive factors independently associated with HIV
seroconversion (after adjustment for age and calendar period as linear terms), were greater
number of lifetime partners, younger age at first sex, alcohol use (including frequency of
alcohol use, CAGE score and binge drinking), greater number of paying clients per month,
inconsistent condom use with clients, and not being pregnant (Table 2). There was no
evidence of an association with hormonal contraceptive use (either oral or injectable).
As risky sexual behaviour may lie on the causal pathway between alcohol use and HIV
seroconversion, we also estimated associations of alcohol and HIV not adjusted for
behavioural variables (aHR=3.98, 95%CI 1.42-11.18 for alcohol use during follow-up;
aHR=3.53, 95%CI 1.25-10.03 for problem drinking on the CAGE score vs not drinking;
aHR=4.45, 95%CI 1.43-13.85 for binge drinking vs not drinking).
There was strong evidence for an association between HIV seroconversion and prevalent
MG infection tested at the enrolment visit (aHR=2.19, 95%CI: 1.11-4.36), with NG
(aHR=5.41, 95%CI: 2.76-10.57) and with TV infection (aHR =2.26, 95%CI: 1.03-4.93)
(Table 3). Similar results were seen in a model in which the RTI/STIs were not adjusted for
each other (results not shown).
Population Attributable Fractions (PAFs)
The estimated PAF of HIV seroconversion for alcohol use was 63.5% (95%CI
6.5%-85.8%). The PAFs for NG, MG and TV were 29.1% (95%CI 11.1-43.5%), 15.5%
(95%CI 0%-30.3%) and 11.9% (95%CI 0%-25.0%) respectively. The PAF for any treatable
RTI/STIs was 70.0% (95%CI 18.8%-87.5%).
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Discussion
This study presents the first 3-years follow-up data from a large closed cohort of female sex
workers who were attending a dedicated clinic offering HIV prevention interventions, in
Kampala. The baseline HIV prevalence of the cohort was 37% and the HIV incidence rate
was 3.66/100 pyr. These are 4-5 times higher than the most recent estimates of national HIV
prevalence (7.5%) and incidence (0.94/100pyr) for women [12].
There was a substantial decline in the HIV incidence rate over the duration of the project.
This is most likely because, in a closed cohort, women at highest risk seroconvert first
leaving behind women at lower risk, and also because of the intervention efforts of the
project.
Reported alcohol use was strongly associated with HIV incidence after adjusting for other
behavioral factors. Due to the high prevalence of alcohol use in this cohort, we estimate that
approximately 65% of new HIV infections in women at high risk could be attributed to
alcohol use if the association is causal. Alcohol is a documented problem in Uganda, which
ranked as the world’s leading consumer of alcohol in 2004, with an estimated annual
average of 19.5 litres of recorded alcohol per capita consumption and an estimated 10 litres
of unrecorded consumption [13]. A systematic review of 10 longitudinal studies in western
countries found strong epidemiological evidence for an association between alcohol use and
HIV incidence (summary adjusted risk ratio (RR)=1.77; 95%CI:1.43-2.19) [14], and similar
results were found in a systematic review and meta-analysis of 11 studies from sub-Saharan
Africa (summary adjusted RR=1.57, 95%CI 1.42-1.72) [15], which included two
longitudinal studies, and these found a similar effect as in the meta-analysis [16,17].
Pathways for a possible causal link between alcohol use and HIV infection include: i)
biological plausibility that heavy alcohol use increases susceptibility to HIV infection,
through its effects on the liver and innate and acquired immune system functioning; ii) the
direct effect of alcohol consumption on cognitive capacity and behaviour, which can affect
behaviours such as consistent condom use or ability to negotiate safe sex; iii) the physical
occupational co-location of sex work in places which sell alcohol.
In addition, there is co-occurrence of alcohol use and risky sexual behaviour among
individuals with risk-taking personality characteristics [18]. A recent narrative review of
studies in sub-Saharan Africa showed that alcohol consumption was associated with an
increase in several risk behaviours that enhance risk of HIV incidence, including
unprotected sex, sex with multiple partners, transactional sex and coercive sex [19]. Brief
interventions (BI) including counselling to encourage people to alter their alcohol use and to
be delivered by health care workers who do not specialize in alcoholism treatment, have
been designed and a recent systematic review of alcohol studies in sub-Saharan Africa found
that such BI gave promising short term results [20]. However, the only randomized
controlled trial of an alcohol-reduction intervention conducted among female sex workers
did not find a significant intervention effect [21]. Further research is urgently needed to
develop and assess the effectiveness of alcohol reduction interventions adapted to population
groups that are exposed to both HIV and alcohol because of the nature of their work.
STIs were also strongly associated with HIV incidence in this cohort. Women with MG
infection at baseline were twice as likely to acquire HIV as those without. Baseline
prevalence of MG in this cohort was 14% and we previously published evidence for an
association with prevalent HIV infection at enrolment (OR=1.52, 95%CI: 1.07-2.17) [9]. As
no specific treatment was given for this bacterial infection, MG may have persisted in some
women, but not in all women, suggesting that the effect of this STI may be under-estimated
in this analysis. Our findings suggest that there is an urgent need to improve screening for
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and treatment of MG infection, especially in HIV-burdened countries. A recently published
case control study from Zimbabwe reported that MG infection increased the risk of HIV
acquisition [22]. Additional studies are planned in our cohort to assess further the
association with HIV incidence. NG and TV infections were also associated with HIV
incidence as was also the case in similar studies in Kenya [23] and Zimbabwe [24].
The prevalence of BV is known to be high in sub-Saharan Africa [25 – 30]. As in clinical
practice only symptomatic infections are treated, it is likely that many prevalent infections
are persistent. Furthermore, in most women BV recurs quickly after treatment [31]. A recent
two-year cohort study in rural Uganda, investigating weekly vaginal flora patterns, found
that 59% of the enrolled women had at least 1 episode of BV over the follow-up time, with
one third of women spending >50% of their time with BV [32]. We did not find significant
evidence of an association between BV and HIV acquisition in this study. Nevertheless, we
had relatively little power to look at this association and as confidence intervals were wide
the data were not inconsistent with two recent meta-analyses of published HIV incidence
studies showing evidence for an association between BV and HIV acquisition [33, 34].
Although the pathogenesis of BV is as yet poorly understood, its role as a risk factor for
HIV and other STIs has recently attracted more interest [35]. Clinical trials are needed to
investigate improved control strategies to reduce the prevalence and persistence of BV.
There was no evidence of an association between intravaginal cleansing with water and soap
and HIV acquisition in our study, although again our data are consistent with the modest
increase in the risk of HIV seroconversion seen in a recent meta-analysis (pooled adjusted
HR 1.24; 95%CI 1.01-1.53) [34].
Our study showed no evidence for an association between hormonal contraception (either
oral or injectable) and HIV acquisition. Previous studies of HIV-1-acquisition risk related to
contraceptive use have had inconsistent results, partly because of variable methodological
quality [36]. Clinical studies have suggested that changes to vaginal structure, cytokine
regulation, CCR5 expression, and cervicovaginal HIV-1 shedding may be possible
mechanisms by which hormonal contraception could influence HIV-1 susceptibility and
infectiousness [37], and a recent prospective HIV acquisition study in Africa found an
overall association with hormonal contraception, especially with injectables (aHR=1.98,
95%CI:1.06–3.68) [38]. Following publication of these results, a WHO expert group was
convened to review the evidence, and issued a statement that women using progestogen-only
injectable contraception should be strongly advised to also always use condoms [39]. In our
cohort, of the 337 HIV negative women at enrolment who were using injectable
contraception, only 28% reported using male condoms.
In conclusion, our study showed that in this vulnerable group, despite regular screening,
treatment and risk reduction education, STIs are important risk factors for HIV acquisition,
which may call for more intensive control measures such as frequent presumptive treatment.
The association between MG and HIV acquisition needs confirmation from longitudinal
studies and more work is required to decide upon control measures of this emerging STI.
Alcohol use is strongly associated with risk of HIV infection, and effective interventions
adapted to population groups with a high prevalence of drinking are urgently needed.
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Figure 1.
HIV incidence by time since enrolment
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Table 1
Socio-demographic factors associated with HIV seroconversion among 646 women at high risk in Kampala,
Uganda
N (%)(1)
HIV sero
converters
/pyr
HIV
incidence
rate/100 pyr
Age adjusted
Hazard Ratio
(95% CI)
Adjusted Hazard
Ratio(2) (95% CI)
Total 42/1147 3.66
Calendar period of follow-up P-trend=0.02 P-trend=0.02
April 08-March 09 1281 (25) 23/338 6.80 1 1
April 09-March 10 1905 (38) 11/492 2.24 0.27 (0.10-0.74) 0.27 (0.10-0.74)
April 10- March 11 1862 (37) 8/317 2.53 0.23 (0.06-0.94) 0.23 (0.06-0.94)
Attended scheduled visits (%) P=0.10 P=0.15
100% 318 (49) 22/692 3.18 1 1
75%-99% 125 (19) 8/252 3.17 0.93 (0.41-2.09) 0.93 (0.41-2.09)
50%-74% 80 (12) 6/141 4.26 1.05 (0.42-2.62) 0.89 (0.35-2.25)
25%-49% 53 (8) 3/55 5.45 1.49 (0.44-5.08) 1.13 (0.32-3.94)
<25% 70 (11) 3/7 40.47 9.38 (2.55-34.49) 7.66 (2.09 -27.97)
Sociodemographic variables at enrolment
Age (y) P-trend=0.01 P-trend=0.009
<25 291 (45) 26/493 5.27 1 1
25-34 297 (46) 15/549 2.73 0.52 (0.28-0.98) 0.54 (0.28-1.02)
35+ 58 (9) 1/104 0.96 0.18 (0.02-1.32) 0.19 (0.02-1.37)
Religion P=0.17 P=0.16
Catholic 264 (41) 11/472 2.33 1 1
Anglican 182 (28) 14/317 4.42 1.90 (0.86-4.18) 1.88 (0.85-4.15)
Muslim 177 (27) 16/316 5.07 2.19 (1.02-4.72) 2.18 (1.01-4.70)
Other 23 (4) 1/42 2.38 0.92 (0.12-7.15) 0.83 (0.11-6.47)
Education level P=0.91 P=0.83
Primary completed 363 (56) 24/ 647 3.71 1 1
Less than primary 283 (44) 18/500 3.60 1.04 (0.56-1.91) 1.07 (0.58-1.98)
Sociodemographic variables during follow-up
Marital status P=0.81 P=0.79
Widow / Divorced 3176 (63) 26/720 3.61 1 1
Currently married 880 (17) 5/185 2.71 0.74 (0.28-1.96) 0.74 (0.28-1.95)
Never married 992 (20) 11/242 4.54 0.88 (0.42-1.84) 0.86 (0.41-1.80)
Having a regular partner P=0.24 P=0.22
No 1009 (20) 11/230 4.79 1 1
Yes 4039 (80) 31/917 3.38 0.65 (0.32-1.30) 0.64 (0.32-1.28)
Source of income(3) P=0.24 P=0.22
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N (%)(1)
HIV sero
converters
/pyr
HIV
incidence
rate/100 pyr
Age adjusted
Hazard Ratio
(95% CI)
Adjusted Hazard
Ratio(2) (95% CI)
Sex work alone 1382 (27) 14/326 4.29 1 1
Sex work & other job 2926 (58) 26/666 3.90 0.87 (0.46-1.67) 0.85 (0.44-1.63)
No sex work 737 (15) 2/154 1.30 0.33 (0.07-1.45) 0.32 (0.07-1.42)
Average price per sex act(4)(5) P=0.42 P=0.42
<5000 UgSh 689 (16) 5/168 2.97 1 1
>= 5000 UgSh 3611 (84) 35/821 4.26 1.47 (0.58-3.77) 1.45 (0.56-3.70)
(1)Number of women for baseline variables (N= 646 women) or number of visits for time-varying variables (n=5048 visits)
(2)Adjusted for age and calendar time
(3)3 missing observations
(4)
Restricted to women involved in sex work; 11 missing observations
(5)5000 Ugandan Shillings = 2 USD
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Table 2
Associations between behavioural and reproductive health factors and HIV seroconversion among 646 women
at high risk in Kampala, Uganda
N (%)(1) HIV sero
converters
/pyr
HIV incidence
rate/
100 pyr
Age adjusted
Hazard Ratio (95%
CI)
Adjusted Hazard
Ratio(2) (95% CI)
Total 42/1147 3.66
Behavioral factors
Number of lifetime partners P-trend=0.06 P-trend=0.02
<20 95 (15) 2/189 1.06 1 1
20-50 106 (16) 7/195 3.59 3.38 (0.70-16.26) 3.35 (0.68-16.37)
>50 or can’t
remember
445 (69) 33/762 4.33 4.00 (0.96-16.67) 4.78 (1.08-21.14)
Age at first sex P=0.01 P=0.05
<=14 220 (34) 21/373 5.64 1 1
15-22 406 (63) 18/740 2.43 0.44 (0.23-0.82) 0.52 (0.27-0.99)
Can’t remember 20 (3) 3/34 8.73 - -
Frequency of alcohol use (at baseline) P=0.05 P-trend=0.06
Not using 160 (25) 4/276 1.45 1 1
Less than once a week 35 (5) 1/71 1.40 1.00 (0.11-8.92) 0.83 (0.09-7.60)
At least once a week 297 (46) 24/526 4.56 3.14 (1.09-9.06) 2.72 (0.94-7.87)
Daily 154 (24) 13/273 4.76 3.26 (1.06-10.01) 2.58 (0.81-8.20)
CAGE (at baseline) P=0.02 P=0.06
Not drinking 160 (25) 4/276 1.45 1 1
Not problem drinking 139(21) 7/255 2.75 1.92 (0.56-6.56) 1.65 (0.48-5.73)
Problem drinking 347(54) 31/616 5.03 3.45 (1.22-9.78) 2.85 (0.99-8.17)
Alcohol use in last 3 months (at follow-up) P=0.002 P=0.008
No 1559 (31) 4/347 1.15 1 1
Yes 3489 (69) 38/800 4.75 3.91 (1.39-10.97) 3.36 (1.17-9.59)
Binge drinking last 3 months (at follow-up) P=0.006 P=0.03
Non drinker 1559 (31) 4/347 1.15 1 1
Never binge 2622 (52) 26/595 4.37 3.63 (1.27-10.42) 3.20 (1.10-9.31)
Ever Binge 867 (17) 12/205 5.85 4.72 (1.51-14.72) 3.87 (1.20-12.52)
Illicit drug use in last 3 months (at follow-up) P=0.50 P=0.32
No 3921 (78) 31/894 3.47 1 1
Yes 112 (22) 11/253 4.35 1.27 (0.64-2.53) 1.44 (0.72-2.88)
Number of paying clients in last month (at follow-up) (3) P=0.05 P=0.04
<5 2632 (51) 19/576 3.29 1 1
5-50 1983 (40) 14/471 2.97 0.85 (0.42-1.70) 0.85 (0.42-1.72)
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N (%)(1) HIV sero
converters
/pyr
HIV incidence
rate/
100 pyr
Age adjusted
Hazard Ratio (95%
CI)
Adjusted Hazard
Ratio(2) (95% CI)
>50 or can’t
remember
425 (8) 9/101 9.27 2.47 (1.10-5.52) 2.50 (1.12-5.57)
Condom use with paying clients in last month (at follow-up) (4) P=0.06 P=0.07
Consistent 2163 (55) 15/501 2.99 1 1
Inconsistent 1749 (45) 22/408 5.39 1.91 (0.99-3.70) 1.83 (0.95-3.54)
Cleansing of the vagina (at follow-up) P=0.65 P=0.74
Cleansing with soap 2449 (49) 21/565 3.71 1 1
Cleansing without soap 2291 (45) 17/515 3.30 0.93 (0.49-1.77) 0.96 (0.51-1.83)
No cleansing 308 (6) 4/66 6.01 1.60 (0.55-4.67) 1.51 (0.52-4.42)
Reproductive health
Pregnant (at follow-up) P=0.02 P=0.01
No 4515 (89) 41/1015 4.04 1 1
Yes 531 (11) 1/131 0.76 0.17 (0.02-1.23) 0.16 (0.02-1.17)
Hormonal contraceptive use in last 3 months (at follow-up) (5) P=0.99 P=0.95
None or other 2491 (55) 23/559 4.11 1 1
Oral 611 (14) 5/140 3.57 0.99 (0.38-2.62) 0.90 (0.33-2.43)
Injectable (Depo-
Provera)
1415 (31) 13/316 4.11 1.02 (0.52-2.02) 0.88 (0.44-1.75)
(1)Number of women for baseline variables (N= 646 women) or number of visits for time-varying variables (n=5048 visits)
(2)Adjusted for age, calendar time, number of lifetime partners, age at first sex, alcohol use during follow-up, number of paying clients in last 3
months, inconsistent condom use with paying clients and being pregnant
(3)
Missing for 8 women
(4)
For women with paying clients in the last month
(5)
For non-pregnant women only
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Table 3
Associations between STI and HIV seroconversion among 646 women at high risk in Kampala, Uganda.
N (%)(1)
HIV sero
converters
/pyr
HIV incidence
rate/
100 pyr
Age adjusted
Hazard Ratio (95%
CI)
Adjusted Hazard
Ratio(2) (95% CI)
Total 42/1147 3.66
Syphilis (3) P=0.39 P=0.34
No infection 4198 (84) 35/937 3.63 1 1
Past infection 371 (7) 1/105 1.91 0.39 (0.05-2.83) 0.30 (0.04-2.25)
Active low titre syphilis (<8) 332 (7) 3/81 6.16 1.12 (0.34-3.66) 0.72 (0.22-2.38)
Active high titre syphilis (8+) 104 (2) 3/19 5.32 2.42 (0.73-8.01) 1.64 (0.48-5.67)
HSV2 serostatus (4) P=0.01 P=0.29
Negative 1196 (24) 6/289 2.08 1 1
Positive 3848 (76) 36/858 4.20 2.70 (1.13-6.49) 1.59 (0.65-3.93)
N. gonorrhoeae (5) P<0.01 P<0.001
Negative 4576 (94) 27/1046 2.58 1 1
Positive 317 (6) 15/64 23.37 7.58 (3.99-14.42) 5.41 (2.76-10.57)
C. trachomatis (5) P=0.01 P=0.15
Negative 4622 (94) 34/1048 3.24 1 1
Positive 271 (6) 8/63 12.73 3.03 (1.37-6.72) 1.91 (0.83-4.38)
T. vaginalis (6) P=0.02 P=0.06
Negative 4505 (92) 33/1024 3.22 1 1
Positive 396 (8) 9/88 10.24 2.74 (1.30-5.76) 2.26 (1.03-4.93)
Bacterial vaginosis (7) P=0.18 P=0.87
Negative 2092 (43) 12/479 2.50 1 1
Intermediate 244 (5) 3/56 5.32 1.96 (0.55-7.01) 1.36 (0.36-5.12)
Positive 2553 (52) 27/575 4.69 1.82 (0.92-3.60) 1.17 (0.58-2.36)
Candida albicans (8) P=0.91 P=0.54
Negative 4545 (93) 39/1032 3.78 1 1
Positive 346 (7) 3/79 3.82 0.93 (0.29-3.03) 1.46 (0.44-4.85)
M. genitalium (baseline) (9) P=0.009 P=0.03
Negative 564 (88) 30/1007 2.98 1 1
Positive 80 (12) 12/136 8.80 2.63 (1.34-5.17) 2.19 (1.11-4.36)
Confirmed VDS (10) P=0.55 P=0.87
No 3080 (61) 21/672 3.12 1 1
Yes 1967 (39) 21/475 4.42 1.21 (0.65-2.24) 1.06 (0.56-1.99)
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N (%)(1)
HIV sero
converters
/pyr
HIV incidence
rate/
100 pyr
Age adjusted
Hazard Ratio (95%
CI)
Adjusted Hazard
Ratio(2) (95% CI)
Confirmed GUD (9) P=0.12 P=0.32
No 4954 (98) 39/1123 3.47 1 1
Yes 92 (2) 3/23 12.93 3.01 (0.91-9.95) 2.02 (0.56-7.20)
Confirmed PID (10) P=0.22 P=0.59
No 4673 (93) 35/1048 3.34 1 1
Yes 374 (7) 7/98 7.14 1.75 (0.75-4.10) 1.28 (0.53-3.06)
(1)Number of women for baseline variables (N= 646 women) or number of visits for time-varying variables (n=5048 visits)
(2)Adjusted for age, calendar time, age at first sexual intercourse, number of lifetime sexual partners, use of alcohol in the past 3 months, number
of paying clients in past 3 months, inconsistent condom use with paying clients in the past 3 months, current pregnancy, and N. Gonorrhoea, T.
Vaginalis and M. Genitalium infections.
(3)43 missing
(4)4 missing
(5)155 missing
(6)147 missing
(7)159 missing
(8)157 missing
(9)2 missing
(10)1 missing
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